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Abstract
The anticancer drug doxorubicin induces the synthesis of nitric oxide, a small molecule that enhances the drug cytotoxicity and reduces
the drug efflux through the membrane pump P-glycoprotein (Pgp). Doxorubicin also induces the translocation on the plasma membrane
of the protein calreticulin (CRT), which allows tumour cells to be phagocytized by dendritic cells. We have shown that doxorubicin elicits
nitric oxide synthesis and CRT exposure only in drug-sensitive cells, not in drug-resistant ones, which are indeed chemo-immunoresistant.
In this work, we investigate the mechanisms by which nitric oxide induces the translocation of CRT and the molecular basis of this
chemo-immunoresistance. In the drug-sensitive colon cancer HT29 cells doxorubicin increased nitric oxide synthesis, CRT exposure
and cells phagocytosis. Nitric oxide promoted the translocation of CRT in a guanosine monophosphate (cGMP) and actin cytoskeleton-
dependent way. CRT translocation did not occur in drug-resistant HT29-dx cells, where the doxorubicin-induced nitric oxide synthesis
was absent. By increasing nitric oxide with stimuli other than doxorubicin, the CRT exposure was obtained also in HT29-dx cells.
Although in sensitive cells the CRT translocation was followed by the phagocytosis, in drug-resistant cells the phagocytosis did not occur
despite the CRT exposure. In HT29-dx cells CRT was bound to Pgp and only by silencing the latter the CRT-operated phagocytosis was
restored, suggesting that Pgp impairs the functional activity of CRT and the tumour cells phagocytosis. Our work suggests that the 
levels of nitric oxide and Pgp critically modulate the recognition of the tumour cells by dendritic cells, and proposes a new potential 
therapeutic approach against chemo-immunoresistant tumours.
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Introduction
The anthracycline doxorubicin has the peculiarity of inducing the
synthesis of nitric oxide, a small signalling molecule which plays
an important role in cell growth, differentiation and apoptosis [1].
The effect of doxorubicin is mediated by the drug-induced activa-
tion of the transcriptional factor NF-B, which in turn up-regulates
the transcription of the inducible nitric oxide synthase (iNOS; EC
1.14.13.39) gene, leading to the production of huge amounts of
nitric oxide [2]. It has been suggested that at least part of the cyto-
toxic effects elicited by doxorubicin are due to the increased nitric
oxide synthesis [3, 4]. Nitric oxide also reduces the rate of dox-
orubicin efflux through ATP-binding cassette (ABC) membrane
pumps, such as P-glycoprotein (Pgp) and multidrug resistance
related protein 3 (MRP3), two transporters that are responsible for
the resistance towards doxorubicin in cancer cells [5]. By nitrating
these proteins on tyrosine residues, nitric oxide reduces Pgp and
MRP3 activity, reversing doxorubicin-resistance in solid tumours
[4, 6]. Notably, in doxorubicin-resistant cells the induction of
iNOS gene is absent, in consequence of the fast drug extrusion;
however, when the nitric oxide levels are increased in resistant
cells by agents other than doxorubicin, the drug efflux is reduced
and the cytotoxicity is restored [4].
A great interest has been raised by the discovery that, besides
exerting a direct anticancer effect, anthracyclines also stimulate
the host immune response against the tumour [7, 8]. It has been
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discovered that the anthracyclines immunogenicity relies on their
ability to induce the tumour cells phagocytosis by immature den-
dritic cells (iDCs). After this step, iDCs are stimulated to further
maturate and to raise a complete immune response against trans-
formed cells [8]. Following doxorubicin exposure, a change in
tumour cell plasma membrane occurs, leading to the exposure of
intracellular proteins, such as calreticulin (CRT), which is recog-
nized by iDCs and triggers the iDCs-mediated phagocytosis [8, 9].
CRT is usually present in the endoplasmic reticulum (ER), where
it acts as a chaperon and a Ca2 sensor protein [8, 10].
We have recently demonstrated that doxorubicin mediates 
the exposure of CRT and the phagocytosis by iDCs thanks to the
induction of iNOS in drug-sensitive cells: indeed neither the
translocation of CRT nor the phagocytosis occurred in the doxoru-
bicin-sensitive cells silenced for iNOS gene. Doxorubicin was
devoid of pro-immunogenic effects also in drug-resistant cells,
where the anthracycline was not able to accumulate at a sufficient
extent to increase the synthesis of nitric oxide [6]. These results
suggested that chemo- and immunoresistance to doxorubicin are
strictly associated, and may both depend on the lack of nitric oxide
synthesis in drug-resistant cells.
In the present work we first investigated the molecular mech-
anisms by which high levels of nitric oxide induce the translocation
of CRT to the cell surface, comparing the doxorubicin-sensitive
human colon cancer HT29 cells and the doxorubicin-resistant
HT29-dx cells. Moreover we observed that nitric oxide was 
sufficient to promote the translocation of CRT followed by the
phagocytosis in drug-sensitive cells and was necessary to elicit
the CRT exposure also in drug-resistant cells, but surprisingly the
drug-resistant cells remained poorly phagocitized even in the
presence of CRT levels superimposable to sensitive cells. We
thus focused on the molecular basis of this strong association
between chemo- and immunoresistance, and we analysed
whether the increased expression of Pgp in drug-resistant cells
may affect the CRT-mediated phagocytosis, thus contributing to
their immunoresistant phenotype.
Materials and methods
Materials
Foetal bovine serum (FBS), penicillin-streptomycin (PS) and
Roswell Park Memorial Institute (RPMI) 1640 were supplied by
Sigma Chemical Co. (St. Louis, MO, USA), plasticware for cell 
culture was from Falcon (BD Biosciences, Bedford, MA, USA).
Electrophoresis reagents were obtained from Bio-Rad Laboratories
(Hercules, CA, USA), the protein content of cell monolayers and
cell lysates was assessed with the bicinchoninic acid kit from
Sigma Chemical Co. Recombinant human tumour necrosis factor-
 (TNF-) was obtained from R&D Systems (Minneapolis, MN,
USA), 8-bromoguanosine-3:5-cyclic monophosphorothioate, 
Rp-isomer (Rp-8-Br-cGMPS) from Calbiochem (San Diego, CA,
USA), latrunculin A was from Enzo Life Sciences International, Inc.
(Plymouth Meeting, PA, USA). When not otherwise specified, all
the other reagents were purchased from Sigma Chemical Co.
Cells
Human colon cancer cells (HT29 cell line, provided by Istituto
Zooprofilattico Sperimentale ‘Bruno Umbertini’, Brescia, Italy)
were cultured in RPMI 1640 medium supplemented with 10%
FBS, 1% PS and 1% L-glutamine, and maintained in a humidified
atmosphere at 37C and 5% CO2. A subpopulation of HT29 cells,
named HT29-dx, characterized by resistance to doxorubicin, was
generated as previously described [4]. In the present study the
drug resistance was previously assessed by measuring the
Pgp/MRP3 expression, the intracellular doxorubicin accumulation
and the drug-induced cytotoxicity, by fluorescence-activated cell
sorting (FACS) analysis of cells positive for annexin V-fluorescein
isothiocyanate (FITC) as described [2] (data not shown).
Nitrite production
Then nitrite production was measured by adding 0.15 ml of cell
culture medium to 0.15 ml of Griess reagent in a 96-well plate, and
after 10 min. incubation at 37C in the dark, the absorbance was
measured at 540 nm with a Packard EL340 microplate reader (Bio-
Tek Instruments, Winooski, VT, USA). A blank was prepared for
each experimental condition in the absence of cells, and its
absorbance was subtracted from the one obtained in the presence
of cells. Nitrite concentration was expressed as nanomoles of
nitrite/mg cell proteins.
Measurement of NOS activity
The procedure described in Ghigo et al. [11] was followed. The
cells were detached with 0.05% v/v trypsin, washed with phos-
phate-buffered solution (PBS), re-suspended at the concentration
of 100 g cell proteins in 0.6 ml of 20 mmol/l Hepes buffer 
(pH 7.2) and sonicated with one 10 sec. burst, using a Labsonic
Sonicator (Hielscher, Teltow, Germany). A total of 15 l of lysate
were withdrawn to assess the protein content. The protease
inhibitors pepstatin (75 mol/l) and leupeptin (20 mol/l) were
added to the cell lysate, which was then mixed with the following
reagents in a 500 l final volume: 0.2 mmol/l NADP, 360 mol/l
L-arginine, 2 mol/l tetrahydrobiopterin, 0.3 mmol/l CaCl2, 
0.2 mmol/l dithiothreitol, 1.8 mmol/l MgCl2, 0.17 mmol/l glucose
6-phosphate and 40 mU/ml glucose 6-phosphate dehydrogenase
(G6PD; from Saccaromyces cerevisiae; EC 1.1.1.49). The
NOS/G6PD reaction mixture was incubated at 37C for 3 hrs, then
heated at 100C for 5 min. to inactivate G6PD. To oxidize the
remaining reduced form of nicotinamide adenine dinucleotide
phosphate (NADPH), which might interfere with the subsequent
Griess reaction, the mixture was incubated with 10 mU/ml 
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L-lactate dehydrogenase (from pig muscle; EC 1.1.1.27) and 
300 mol/l sodium pyruvate at 37C for 5 min. The nitrite pro-
duction was measured using the Griess reagent as described.
Blanks were prepared by replacing the cell lysate with Hepes
solution, in the NOS/G6PD reaction mix, which was subjected to
the same experimental procedure used for samples containing
lysate. The NOS activity was expressed as nanomoles
nitrites/min./mg protein.
Analysis of cell surface CRT
For flow cytometry analysis, cells were washed twice with PBS,
rinsed with 1 ml of 0.25% w/v PBS-bovine serum albumin (BSA)
and centrifuged at 10,000  g for 5 min. The pelleted cells were
incubated for 45 min. (4C) with an anti-CRT rabbit polyclonal
antibody (Affinity Bioreagents, Rockford, IL, USA), diluted 1:500
in 100 l of PBS-BSA, then washed and incubated with 100 l
anti-rabbit FITC-conjugated antibody (diluted 1:50 in PBS-BSA)
for 30 min. at 4C in the dark. After fixation in paraformaldehyde
2%, cells were re-suspended in 500 l PBS-BSA and analysed
using a FACS-Calibur system (BD Biosciences). For each analysis
10,000 events were collected. The percentage of fluorescent cells
was calculated by the Cell Quest software (BD Biosciences).
Control experiments included incubation of cells with non-
immune isotypic antibodies followed by the appropriate labelled
secondary antibody. Because doxorubicin has a strong autofluo-
rescence which might lead to misinterpret flow cytometry results,
we validated FACS experiments by measuring the CRT exposure in
biotinylation assays, using the Cell Surface Protein isolation kit
from Thermo Fisher Scientific, Inc. (Rockford, IL, USA), as previ-
ously reported [6]. A total of 25 g of the biotinylated proteins
were separated by 10% SDS-PAGE, transferred to a polyvinylidene
fluoride (PVDF) membrane sheet (Immobilon-P. Millipore,
Billerica, MA, USA) and probed with the anti-CRT rabbit polyclonal
antibody (diluted 1:1000 in PBS-BSA 1%). The whole cellular con-
tent of CRT was measured after ultracentrifugation of the cell
lysates at 100,000  g for 1 hr. A total of 10 g of the pelleted
proteins were separated by 10% SDS-PAGE, transferred to PVDF
membrane sheet and probed with the anti-CRT antibody. The
membranes were washed with PBS-Tween 0.1% and subjected for
1 hr to a horseradish peroxidase-conjugated anti-rabbit antibody
(diluted 1:3000 in PBS-Tween 0.1% with blocker non-fat dry milk
5%, Bio-Rad Laboratories). The membranes were washed again
and the proteins were detected by enhanced chemiluminescence
(PerkinElmer, Waltham, MA, USA).
In vitro phagocytosis assay
iDCs were generated as described [12]. The tumour cells were
green-stained with PKH2-FITC (Sigma Chemical Co.), washed
twice and incubated for 20 hrs at 37C with 1  105 iDC at a 1:1
ratio, and the mixed culture was stained with the phycoerythrin
(PE)-conjuganted anti-CD80 antibody (BD Bioscience) for 20 min.
at 4C. Phagocytosis of tumour cells by iDC was assessed by flow
cytometric analysis as the percentage of double-stained (FITC plus
PE) versus red (PE) stained cells on a total of 10,000 events, using
the DIVA software (FacsCanto system, BD Biosciences). A phago-
cytosis assay was performed by co-incubating iDC and tumour
cells at 4C, instead of 37C, and the percentage of double-stained
cells obtained after the incubation at 4C was subtracted from 
the one obtained after a 37C incubation. The phagocytosis rate
was expressed as phagocytic index, calculated as previously
reported [9].
Immunofluorescence microscopy
Cells were seeded on sterile glass cover slips and incubated
under the experimental conditions indicated in ‘Results’, then
rinsed with PBS and fixed with 4% w/v paraformaldehyde for 
15 min. To visualize intracellular CRT, the samples were perme-
abilized with 0.1% v/v Triton-100 for 5 min. on ice. Both 
permeabilized and non-permeabilized cells (used to detect 
surface CRT) were washed three times with PBS and stained
with a rabbit polyclonal anti-CRT antibody (diluted 1:100 in PBS
containing 1% FBS) for 1 hr at room temperature. After washing,
the samples were incubated with a biotinylated goat anti-rabbit
IgG antibody (diluted 1:50; Vector Laboratories, Burlingame, CA,
USA) for 30 min. at room temperature, washed and incubated
with fluorescein avidin D (diluted 1:300, Vector Laboratories) 
for further 30 min. at room temperature. To visualize 
actin cytoskeleton, cells were co-incubated with phalloidin-
tetramethylrhodamine B isothiocyanate (diluted 1:1000). Finally
all samples were washed with PBS, stained with 4,6-Diamidino-
2-phenylindole dihydrochloride (DAPI; diluted 1:20,000) and
washed again. The cover slips were mounted with 4 l of Gel
Mount Aqueous Mounting and examined with a Leica DC100 
fluorescence microscope (Leica Microsystems GmbH, Wetzlar,
Germany). For each experimental point, a minimum of five
microscopic fields were examined.
Western blot analysis
Cells were washed twice with PBS, then lysed in heated lysis
buffer (25 mmol/l Hepes, 135 mmol/l NaCl, 1% v/v Nonidet P-40,
5 mmol/l ethylenediaminetetraacetic acid (EDTA), 1 mmol/l ethyl-
ene glycol tetraacetic acid (EGTA), 1 mmol/l ZnCl2 and 10% v/v
glycerol) and sonicated with one 10 sec. burst, using a Labsonic
Sonicator (Hielscher). After centrifugation (13,000  g for 15 min.)
the protease inhibitor cocktail III (100 mmol/l 4-(2-Aminoethyl)
benzenesulfonyl fluoride hydrochloride (AEBSF), 80 mol/l apro-
tinin, 5 mmol/l bestatin, 1.5 mmol/l E-64, 2 mmol/l leupeptin, and
1 mmol/l pepstatin; Calbiochem), 2 mmol/l phenylmethylsulfonyl flu-
oride and 1 mmol/l NaVO4 were added to the supernatant. A total
of 25 g cell proteins were separated by SDS-PAGE, transferred
to PVDF membrane sheets and probed with an anti-vasodilator-
stimulated phosphoprotein (VASP) (rabbit polyclonal, diluted 1:500
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in PBS-BSA 1%; Cell Signaling Technology, Inc., Danvers, MA,
USA) or an anti-phospho(Ser 239)-VASP (mouse monoclonal,
diluted 1:500 in PBS non-fat dry milk 3%, Millipore) antibody.
In co-immunoprecipitation experiments, 100 g of total cell
proteins or biotinylated proteins, re-suspended in 200 l TEEN-
Triton buffer (Tris 50 mmol/l, EDTA 1 mmol/l, EGTA 1 mmol/l, NaCl
150 mmol/l, Triton X-100 1% v/v), were immunoprecipitated
overnight with the anti-CRT antibody (diluted 1:100), then sub-
jected to 7% SDS-PAGE and probed for Pgp (with a rabbit poly-
clonal antibody, diluted 1:250 in PBS non-fat dry milk 5%, Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The proteins were
detected by enhanced chemiluminescence as described above.
The densitometric analysis of Western blots was performed with
the ImageJ software (http://rsb.info.nih.gov/ij/) and expressed as
arbitrary units, where ‘1 unit’ is the mean band density of the
experimental condition ‘HT29 CTRL’.
Small interfering RNA (siRNA)
A total of 200,000 cells were plated and cultured in RPMI 1640 
containing 10% FBS. After 24 hrs, cells were washed with 2 ml
siRNA transfection medium (Santa Cruz Biotechnology, Inc.)
and incubated for 6 hrs with 1 ml siRNA transfection medium
containing 5 l of siRNA transfection reagent (Santa Cruz
Biotechnology, Inc.) and 50 pmol of Pgp specific siRNA (Santa
Cruz Biotechnology, Inc.). In each set of experiments, one 
dish was treated with 50 pmol of Control siRNA-A (Santa Cruz
Biotechnology, Inc.), a scrambled non targeting 20-to 
25-nucleotide siRNA, designed as a negative control to assess
siRNA specificity. At the end of the incubation, 1 ml of RPMI
1640 containing 1% PS and 20% FBS was added for 24 hrs;
cells were washed and cultured for 72 hrs in RPMI 1640 with
1% PS and 10% FBS. To verify the siRNA efficacy, the expres-
sion of Pgp protein was analysed by Western blotting as
reported above. The expression of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), chosen as a housekeeping gene, was
checked with a specific antibody (from rabbit, diluted 1:500 in
PBS-BSA 1%, Santa Cruz Biotechnology, Inc.).
Intracellular doxorubicin accumulation
Cells were grown in 35-mm-diameter Petri dishes and incubated
in RPMI 1640 for 3 hrs with 5 mol/l doxorubicin, and then the
intracellular content of the drug was detected fluorimetrically as
previously reported [4].
Statistical analysis
All data in text and figures are provided as mean 	 S.E. The
results were analysed by a one-way ANOVA and Tukey’s test. P
 0.05
was considered significant.
Results
Doxorubicin fails to increase CRT exposure 
and HT29 cells phagocytosis when nitric oxide
synthesis is inhibited
Doxorubicin increased the activity of NOS enzyme (Fig. 1A) and
the synthesis of nitrite (Fig. 1B) in HT29 cells; both the events
were reversed by the NOS inhibitor NG-monomethyl-L-arginine
(L-NMMA). The nitric oxide scavenger 2-phenyl-4,4,5,
5-tetramethylimidazoline-1-oxyl-3-oxide (PTIO), which per se
did not affect the enzymatic activity of NOS (Fig. 1A), effectively
reduced the increase of nitrite elicited by the anthracycline 
(Fig. 1B). By labelling the surface proteins of HT29 cells with
biotin (Fig. 1C) and by employing flow cytometry (Fig. 1D), 
we showed that doxorubicin increased the amount of plasma
membrane associated CRT in HT29 cells and that this response
was lowered by PTIO and L-NMMA. No change in total CRT was
detected in the presence of doxorubicin, PTIO and L-NMMA
(Fig. 1C). Doxorubicin also enhanced the phagocytosis of HT29
cells by iDCs, but when the nitric oxide scavenger or the NOS
inhibitor were co-incubated with the drug, the phagocytosis was
lowered (Fig. 1E).
On the contrary, doxorubicin, which was less accumulated in
HT29-dx cells [6], did not elicit any increase of nitric oxide 
synthesis (Fig. 1A and B), CRT translocation on plasma membrane 
(Fig. 1C and D) and phagocytosis (Fig. 1E) in drug-resistant cells.
PTIO and L-NMMA were devoid of effects on all these parameters
in HT29-dx cells (Fig. 1A–E). HT29-dx cells exhibited a basally
lower activity of NOS enzyme (Fig. 1A), a result already reported
in this experimental model [6]. Unexpectedly, we observed that
the rate of phagocytosis in untreated HT29-dx cells was lower than
in HT29 cells (Fig. 1E).
Nitric oxide promotes the translocation of CRT 
in a cGMP-dependent way, via the actin
cytoskeleton remodelling
Amongst its several target enzymes, nitric oxide may activate a
soluble guanylate cyclase (sGC) and increase the synthesis of
cGMP, which in turn promotes the activation of a cGMP-depend-
ent protein kinase (PKG). This event accounts for several effects
of nitric oxide such as smooth muscle relaxation, platelet aggre-
gation and cytoskeleton remodelling [13]. Therefore we meas-
ured the expression of cell surface CRT in the presence of the
nitric oxide donor S-nitrosopenicillamine (SNAP), of the stable
cGMP analogue 8-Br-cGMP, of the sGC inhibitor 1H-[1,2,4]oxa-
diazolo-[4,3-a]quinoxalin-1-one (ODQ) and of the PKG inhibitor
Rp-8-Br-cGMPS. 8-Br-cGMP was as effective as SNAP in induc-
ing the translocation of CRT (Fig. 2A and B). On the contrary,
ODQ and Rp-8-Br-cGMPS greatly reduced the effect of SNAP
(Fig. 2A and B). Remarkably, the response to cGMP pathway
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modulators was similar in doxorubicin-sensitive and doxoru-
bicin-resistant cells.
Immunofluorescence analysis revealed that untreated HT29
and HT29-dx cells had no detectable amounts of CRT on plasma
membrane, whereas the great majority of the protein was con-
tained within cells (Fig. S1). Nitric oxide promoted the transloca-
tion of CRT in a time-dependent way: indeed CRT was nearly unde-
tectable 10 min. after the application of SNAP, but became more
appreciable after 30 min. At 1 hr the fluorescence was more
intense and detected on larger portions of cell surface. Again, the
response to the nitric oxide donor was superimposable in chemo-
sensitive and chemo-resistant cells (Fig. S1), as observed in flow
cytometry analysis (Fig. 2A) and biotinylation assay (Fig. 2B).
A downstream effector of PKG is the VASP, which, after being
phosphorylated on serine by PKG, has a prominent role in actin
cytoskeleton remodelling [14]: in HT29 and HT29-dx cells the
Fig. 1 Effects of PTIO and L-NMMA on doxorubicin-induced nitric oxide synthesis, CRT translocation and tumour cells phagocytosis. HT29 and HT29-dx
cells were cultured for 6 hrs in the absence (CTRL) or in the presence of doxorubicin (5 mol/l, DOX), alone or together with the nitric oxide scavenger
PTIO (100 mol/l, PT) or the NOS inhibitor L-NMMA (1 mmol/l, NM). Then the following assays were performed. (A) The NOS activity was measured in
the cell lysates by a spectrophotometric assay. Measurements were performed in triplicate. Data are presented as means 	 S.E.  (n  3). Vs CTRL HT29:
*P 
 0.01; versus DOX: P 
 0.001. (B) Colorimetric detection of nitrite amounts in cell culture medium was performed in duplicate. Data are presented
as means 	 S.E. (n  4). Vs CTRL HT29: *P 
 0.001; versus DOX: P 
 0.05. (C) Western blot analysis of biotinylated surface CRT and of total CRT
was performed as reported under ‘Materials and methods’. The figure is representative of three experiments with similar results. The band density ratio
between surface and total CRT was expressed as arbitrary units. Vs CTRL HT29: *P 
 0.001; versus DOX: P 
 0.01. (D) Flow cytometry analysis of
cells positive for surface CRT was performed in duplicate as described in ‘Materials and methods’. Data are presented as means 	 S.E. (n  3). Vs CTRL
HT29: *P 
 0.001; versus DOX: P 
 0.02. (E) The phagocytosis of HT29 and HT29-dx cells by iDCs was measured in duplicate by flow cytometry (see
‘Materials and methods’ for details). Data are presented as means 	 S.E. (n  3). Vs CTRL HT29: *P 
 0.05; versus DOX: P 
 0.05.
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phosphorylation of VASP was absent under basal conditions,
became detectable in the presence of SNAP and 8-Br-cGMP, and
was reduced when SNAP was co-incubated with ODQ and Rp-8-
Br-cGMPS (Fig. 2C). Total VASP did not vary in any experimental
condition (Fig. 2C).
To evaluate the involvement of actin cytoskeleton in the nitric
oxide/cGMP-mediated translocation of CRT, we analysed the effect
of latrunculin A, a specific inhibitor of G-actin monomers assem-
bly: interestingly, SNAP and 8-Br-cGMP were not able to elicit any
detectable exposure of CRT in both HT29 and HT29-dx cells, when
co-incubated with latrunculin A (Fig. 3A and B). Untreated HT29
and HT29-dx cells showed a widespread intracellular actin distri-
bution, with a continuous ring in the sub-plasma membrane
region (Fig. 3C). Such a distribution was not modified by the
SNAP, whereas latrunculin, both alone and in the presence of the
nitric oxide donor, induced a pronounced change in cell morphol-
ogy, disrupted the sub-plasma membrane ring and condensed
actin in selective areas of cells surface. Moreover when co-incu-
bated with latrunculin, SNAP was not able to elicit the transloca-
tion of CRT on cell plasma membrane (Fig. 3C).
Fig. 2 Effect of nitric oxide/cGMP pathway on CRT translocation. HT29 and HT29-dx cells were treated for 1 hr with fresh medium (CTRL), SNAP 
(100 mol/l, SN), 8-Br-cGMP (10 mol/l, 8Br), ODQ (10 mol/l, ODQ) and Rp-8-Br-cGMPS (10 mol/l, Rp8Br), in different combinations, then sub-
jected to the following investigations. (A) The percentage of cells positive for surface CRT was measured in duplicate by FACS analysis as described in
‘Materials and methods’. Data are presented as means 	 S.E. (n  3). Vs CTRL HT29: *P 
 0.001; versus SN: P 
 0.002. (B) Biotinylated surface CRT
and total CRT were measured in Western blotting experiments, as reported in ‘Materials and methods’. The figure is representative of three experiments
with similar results. The band density ratio between surface and total CRT was expressed as arbitrary units. Vs CTRL HT29: *P 
 0.001; versus SN: 
P 
 0.02. (C) Western blot analysis of VASP and phospho(Ser239)-VASP was performed on cytosolic extracts as described under ‘Materials and meth-
ods’. The figure is representative of three experiments with similar results. The band density ratio between phospho(Ser239)-VASP and total VASP was
expressed as arbitrary units. Vs CTRL HT29: *P 
 0.01; versus SN: P 
 0.02.
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Taken together these results indicate that nitric oxide elicits the
translocation of CRT on plasma membrane, via the cGMP/PKG/
VASP activation and the remodelling of actin cytoskeleton. This
pathway is as active in chemosensitive as in chemoresistant cells.
CRT exposure is increased by nitric oxide in both
HT29 and HT29-dx cells, but is followed by
phagocytosis only in doxorubicin-sensitive cells
TNF-, a potent inducer of iNOS, significantly increased the NOS
activity (Fig. 4A), the nitrite levels (Fig. 4B) and the CRT translocation
(Fig. 4C and D) in both doxorubicin-sensitive and doxorubicin-
resistant cells. PTIO, which lowered the levels of nitrite (Fig. 4B)
without affecting per se NOS activity (Fig. 4A), also decreased the
exposure of CRT (Fig. 4C and D). In parallel TNF- induced,
whereas PTIO reduced, the index of phagocytosis of HT29 cells by
iDCs (Fig. 4E). Despite the increase of nitrite and CRT, TNF- did
not induce the iDCs-mediated uptake of HT29-dx cells, which were
less phagocytized than drug-sensitive cells in each experimental
condition (Fig. 4E).
Doxorubicin and the nitric oxide donor SNAP per se increased
the nitrite levels (Fig. 5A) and the CRT exposure (Fig. 5C and D) 
in HT29 cells, displaying an additive effect when co-incubated 
(Fig. 5A, C and D). SNAP did not modify the activity of NOS, which
was raised by doxorubicin in sensitive cells and remained super-
imposable to the control cells in all the other conditions (Fig. 5B),
but increased the nitrite amounts by releasing nitric oxide 
(Fig. 5A). When SNAP was co-incubated with doxorubicin in dox-
orubicin-resistant cells, where the drug alone was devoid of effect,
the nitrite amount was significantly increased (Fig. 5A) and the
CRT exposure was induced (Fig. 5C and D). Cisplatin, an anti-
cancer agent which did not affect the nitric oxide synthesis 
(Fig. 5A and B) was not able to elicit any translocation of CRT 
(Fig. 5C and D) or to promote the phagocytosis (Fig. 5E). However,
when SNAP was added to cisplatin, the CRT expression became
detectable in plasma membrane (Fig. 5C and D) and the uptake of
HT29 cells by iDCs was significantly raised (Fig. 5E). Again, a 
Fig. 3 Effect of cytoskeleton remodelling in
the nitric oxide/cGMP-mediated transloca-
tion of CRT. HT29 and HT29-dx cells were
treated for 1 hr with fresh medium (CTRL),
SNAP (100 mol/l, SN), 8-Br-cGMP (10 mol/
l, 8Br), latrunculin A (200 nmol/L, LA), in dif-
ferent combinations, then the following
experiments were performed. (A) The per-
centage of cells positive for surface CRT,
obtained by FACS analysis, was calculated in
duplicate as described in ‘Materials and
methods’. Data are presented as means 	
S.E. (n  3). Vs CTRL HT29: *P 
 0.02 ver-
sus SN: P 
 0.02. (B) Biotinylated surface
CRT and total CRT were measured by
Western blot analysis as reported in
‘Materials and methods’. The figure is repre-
sentative of three experiments with similar
results. The band density ratio between sur-
face CRT and total CRT was expressed as
arbitrary units. Vs CTRL HT29: *P 
 0.001;
versus SN: P 
 0.01. (C) Cells were stained
with phalloidin-tetramethylrhodamine B
isothiocyanate to visualize actin fibres; 
surface CRT was detected by an anti-CRT
antibody, as specified in ‘Materials and 
methods’. The micrographs are representative
of three experiments with similar results.
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dissociation between the CRT exposure and the phagocytosis was
observed in HT29-dx cells, where in the presence of cisplatin plus
SNAP, the CRT translocation on cell surface increased (Fig. 5C and
D), but the phagocytosis did not (Fig. 5E).
These data gave us further evidence that nitric oxide, gener-
ated by an iNOS inducer as well as released by a nitric oxide
donor, was necessary to promote the CRT translocation in both
doxorubicin-sensitive and doxorubicin-resistant tumour cells,
but it was sufficient to induce phagocytosis by iDCs only in the
drug-sensitive ones.
In HT29-dx cells CRT is associated to Pgp, which
exerts an inhibitory effect on the phagocytosis
To analyse why the increased amount of surface CRT was not relat-
able to an increased phagocytosis in HT29-dx cells, we investigated
whether Pgp, a membrane protein which is overexpressed in HT29-
dx cells, but not in HT29 cells [4, 6], might interfere with the func-
tional activity of the surface CRT or with the phagocytosis of drug-
resistant cells. We first assessed if Pgp was physically associated
to CRT: we immunoprecipitated with an anti-CRT antibody the cell
extracts enriched with the ER membranes (where the vast majority
of CRT resides) or containing the cell surface biotinylated proteins;
then we probed the immunoprecipitated samples with an anti-Pgp
antibody (Fig. 6). In HT29 cells, where the expression of Pgp was
low (Fig. 7A), we did not detect any association between Pgp and
CRT (Fig. 6A). On the contrary, in ER extracts derived from HT29-
dx cells, Pgp co-immunoprecipitated with CRT (Fig. 6A). Such an
association was detected in untreated cells and was not affected by
doxorubicin or SNAP (Fig. 6A). The nitric oxide donor SNAP was
the only agent able to induce the exposure of CRT in the plasma
membrane in HT29-dx cells (Figs 5B, C and 6B): following SNAP
incubation, we observed a co-immunoprecipitation of CRT and Pgp
also in the cell extracts containing surface biotinylated proteins
(Fig. 6B). This phenomenon was absent in untreated cells and in
HT29-dx cells exposed to doxorubicin (Fig. 6B). Such a result sug-
gests that Pgp was bound to CRT in ER and that this association
was not lost during the translocation on the plasma membrane of
doxorubicin-resistant cells.
To further clarify whether the interaction between CRT and Pgp
has a functional role in the immunoresistance of HT29-dx cells, we
knocked down Pgp with a siRNA approach. Besides reducing the
protein expression levels in HT29-dx cells (Fig. 7A), the silencing of
Pgp raised the accumulation of doxorubicin to a level superimposable
to that of not-silenced HT29-dx cells treated with SNAP (Fig. 7B).
Fig. 4 Effects of TNF- on doxorubicin-induced
nitric oxide synthesis, CRT translocation and tumour
cells phagocytosis. HT29 and HT29-dx cells were
cultured for 6 hrs in the absence (CTRL) or presence
of the iNOS inducer TNF- (50 ng/ml, TNF), alone or
together with the nitric oxide scavenger PTIO 
(100 mol/l, PT), then cells were subjected to the
following investigations. (A) Spectrophotometric
detection of the NOS activity in cell lysates.
Measurements were performed in triplicate. Data
are presented as means 	 S.E. (n  3). Vs CTRL
HT29: *P 
 0.001; versus CTRL HT29-dx: P 

0.005. (B) The nitrite levels in the culture super-
natant, assessed by Griess method, were measured
in duplicate. Data are presented as means 	 S.E. 
(n  4). Vs CTRL HT29: *P 
 0.01; versus TNF: 
P 
 0.005. (C) Biotinylated surface CRT and total
cell CRT expression was measured by Western blot
experiments, as reported under ‘Materials and
methods’. The figure is representative of three
experiments with similar results. The band density
ratio between surface and total CRT was expressed
as arbitrary units. Vs CTRL HT29: *P 
 0.01; ver-
sus TNF: P 
 0.005. (D) The percentage of cells
positive for surface CRT was performed in duplicate
by FACS analysis as described in ‘Materials and
methods’. Data are presented as means 	 S.E. 
(n  3). Vs CTRL HT29: *P 
 0.05; versus TNF: 
P 
 0.05. (E) The rate of HT29 and HT29-dx cells
phagocytized by iDCs was measured in duplicate by
flow cytometry (see ‘Materials and methods’ for
details). Data are presented as means 	 S.E. (n 3).
Vs CTRL HT29: *P 
 0.05; versus TNF: P 
 0.05.
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Wild-type HT29-dx and HT29-dx Pgp– cells did not differ in nitrite
levels (Fig. 7B) and surface CRT amounts (Fig. 7C) under basal con-
ditions and after the incubation with SNAP. On the contrary, doxoru-
bicin was able to increase the nitric oxide synthesis (Fig. 7B) and the
CRT exposure on the plasma membrane (Fig. 7C) only in HT29-dx
cells silenced for Pgp, where the drug intracellular content was sig-
nificantly higher (Fig. 7B). As far as the uptake by iDCs is concerned,
untreated HT29-dx Pgp–, which exhibited a low exposure of CRT
(Fig. 7C), were poorly phagocytized, similar to HT29-dx cells 
(Fig. 7D). However, in the presence of doxorubicin or SNAP, which
both increased the surface CRT levels in HT29-dx Pgp– cells 
(Fig. 7C), the silencing of Pgp induced the uptake by iDCs, suggest-
ing that the overexpression of Pgp exerts a negative control on the
CRT-dependent phagocytosis of drug-resistant cells (Fig. 7D).
Discussion
The combination of conventional anticancer drugs to immunostim-
ulating agents has recently obtained promising results in tumour
mice models and in clinical trials [15, 16]. Anthracyclines, like dox-
orubicin, are useful tools in the chemoimmunotherapy, because
they are the only anticancer drugs with a proved stimulating effect
on macrophages [17], lymphocytes [18] and DCs [8]. Most anti-
cancer drugs elicit in tumour cells an apoptotic death, which is con-
sidered not immunogenic, in opposition to a necrotic death, which
releases in the microenvironment several tumour antigens, recog-
nized by iDCs [8]. Doxorubicin exerts both an apoptotic and an
immunogenic cell death: indeed following the drug administration,
several intracellular proteins, like CRT, are exposed on the plasma
membrane and trigger the tumour cells uptake by iDCs [8]. Besides
inducing CRT translocation, doxorubicin is also able to increase the
synthesis of nitric oxide, which may act as a tumoricidal agent, as
an immunomodulator agent [19] and as an inhibitor of the doxoru-
bicin efflux through ABC transporters [4, 6]. We have recently
demonstrated that nitric oxide is also the mediator of the CRT
translocation in the HT29 doxorubicin-sensitive colon cancer cells:
after this event, tumour cells are phagocytized by iDCs, which
acquired the competence to prime alloantigen reactive lympho-
cytes [6]. No translocation of CRT is elicited by doxorubicin when
the synthesis of nitric oxide is lacking, like in HT29 cells silenced
for iNOS gene, or in doxorubicin-resistant HT29-dx cells, where the
drug is actively extruded by Pgp and is not accumulated at a suffi-
cient amount to raise the nitric oxide synthesis [6].
In the present work we first investigated by which mechanisms
nitric oxide could exert such an effect. In chemosensitive HT29
Fig. 5 Effect of SNAP and anticancer drugs
on CRT translocation and phagocytosis in
HT29 and HT29-dx cells. HT29 and HT29-dx
cells were incubated for 6 hrs in the absence
(CTRL) or presence of the nitric oxide donor
SNAP (100 mol/l, SN), doxorubicin (5 mol/l,
DOX) or cisplatin (10 mol/l, Pt), in 
different combinations. Then the following
investigations were performed. (A) The
nitrite amount was detected in the super-
natant of cell cultures in duplicate, as
described in ‘Materials and methods’. Data
are presented as means 	 S.E. (n  4). Vs
CTRL HT29: *P 
 0.005; versus DOX: P 

0.001; versus Pt: P 
 0.001. (B) The NOS
activity was measured spectrophotometri-
cally in the cell lysates. Measurements were
performed in triplicate. Data are presented
as means 	 S.E. (n  3). Vs CTRL HT29:
*P 
 0.005. (C) Western blot analysis of
biotinylated surface CRT and of total cell
CRT was performed as reported under
‘Materials and methods’. The figure is repre-
sentative of three experiments with similar
results. The band density ratio between 
surface and total CRT was expressed as
arbitrary units. Vs CTRL HT29: *P 
 0.001;
versus DOX: P 
 0.002; versus Pt: P 

0.02. (D) The surface expression of CRT was
assessed by flow cytometry analysis (see ‘Materials and methods’ for details). Data are presented as means 	 S.E. (n  4). Vs CTRL HT29: *P 
 0.001;
versus DOX: P
 0.01; versus Pt: P
 0.02. (E) The uptake of HT29 and HT29-dx cells by iDCs was evaluated in duplicate by flow cytometry, as reported
in ‘Materials and methods’. Data are presented as means 	 S.E. (n  3). Vs CTRL HT29: *P 
 0.01; versus Pt: P 
 0.02.
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cells incubated with doxorubicin, in the presence of a nitric oxide
scavenger or a NOS inhibitor, the nitrite increase elicited by the
anthracycline, the CRT translocation and the cells phagocytosis by
iDCs were all reduced. On the contrary, in drug-resistant HT29-dx
cells, where nitric oxide levels were not modulated by doxorubicin,
PTIO and NMMA, CRT translocation and phagocytosis by iDCs
remained low. Interestingly, NOS activity was lower in untreated
HT29-dx cells than in HT29 cells, although no significant difference
was detected in the nitrite levels between these cell populations:
such a discrepancy is likely due to the higher sensitivity of the
spectrophotometric assay of NOS activity towards the colorimetric
Griess method for nitrite detection [11]. We did not observe any
variation in the total CRT expression, despite significant changes in
the CRT levels on the plasma membrane. Most CRT usually resides
in ER and is absent on plasma membrane, where only small
amounts of CRT translocate; it has been suggested that, although
the fraction of CRT in ER does not change, small variations in the
plasma membrane fraction may be sensed as an effective ‘eat me’
signal by iDCs [9]. The appearance of small but detectable amounts
of CRT was a powerful eating marker also in our experimental
model. This event has been reported to be the first step a more
complex activation of the host immune system against the tumour.
For example the exposure of CRT on the mouse CT26 colon
cells surface has been shown to trigger the activation of immune
system cells in mice xenografts [9] and the up-regulation of CRT
gene in colon cancers with microsatellite instability has been
associated with a more pronounced lymphocytic infiltrate, a more
active immune response and a better prognosis of patients [20].
In keeping with these observations, we have previously observed
that in HT29 cells the CRT exposure increased the tumour cell
uptake and the progression of immature DCs to an antigen-pre-
senting mature phenotype [6].
Several mechanisms have been invoked to explain how CRT
appears on the plasma membrane following anthracyclines
administration. Because such translocation occurs in both enucle-
ated and nucleated tumour cells, the increase of CRT on the cell
surface is not attributable to augmented gene transcription [9].
Some experimental evidence show that agents preventing the ER
stress, such as the inhibitors of PP1/GADD34 complex, facilitate
the CRT translocation. However the inhibition of PP1/GADD34 per
se is not sufficient to evoke an immunogenic death of tumour cells
[9]. The human neuroblastoma SH-SY5Y cell line is completely
refractory to translocate CRT in response to mitoxantrone, but the
depletion of Ca in ER partially restores this CRT translocation
[21]. Nitric oxide has already been reported to lower the Ca
level in ER [22] and we cannot exclude that this mechanism could
be implicated in the translocation of CRT from ER to the plasma
membrane. However, our results suggest an involvement of the
cGMP/PKG pathway in such a translocation in colon cancer cells:
indeed both the nitric oxide donor SNAP and the sGC activator 8-
Br-cGMP increased CRT exposure, which was prevented by
inhibiting sGC or PKG. When PKG is activated it can in turn phos-
phorylate and activate the serine–threonine kinase VASP [14], an
event which was observed in both HT29 and HT29-dx cells stim-
ulated by SNAP or 8-Br-cGMP and was reduced when the
sGC/PKG pathway was blocked. Active VASP deeply affects the
activity and localization of intercellular junction proteins and inte-
grins, owing to its effect on actin cytoskeleton [13]. Interestingly,
the anthracycline-mediated exposure of CRT in mouse colon cells
was reduced by inhibiting the actin fibres remodelling, whereas
was unaffected by agents disrupting microtubules [9]. In our
experimental conditions, latrunculin A, a toxin inhibiting the poly-
merization of G-actin, blocked the CRT translocation elicited by
SNAP or 8-Br-cGMP. Therefore we can suggest that nitric oxide
promotes the exposure of CRT by activating the cGMP/PKG/VASP
pathway and by inducing a remodelling of the actin fibres. Nitric
oxide promoted a time-dependent translocation on plasma mem-
brane of CRT, which was concentrated in selective portions of cell
surface. Such a patchy distribution was observed also in CT26
colon cancer cells exposed to mitoxantrone [23], suggesting a
preferential localization of CRT in specific microdomains of
plasma membrane. In CT26 cells CRT co-localizes with ERp57,
another protein of ER, which translocates on cell surface and
becomes an integral component of the major histocompatibility
complex class I system [23]. We cannot exclude that nitric oxide
promotes a co-translocation of CRT and ERp57 from ER to plasma
membrane also in HT29 colon cancer cells.
Notably no differences in the translocation of CRT induced 
by the nitric oxide/cGMP-pathway were detected between
Fig. 6 Co-immunoprecipitation of CRT and Pgp in HT29 and HT29-dx cells.
Cells were incubated for 6 hrs in the absence (CTRL) or presence of dox-
orubicin (5 mol/l, DOX) or SNAP (100 mol/l, SN), then they were lysed
and subjected to ultracentrifugation to isolate the ER-enriched fraction (A).
In parallel, in an aliquot of cells incubated under the same experimental
conditions, the surface proteins were isolated by a biotinylation assay (B).
Each sample was immunoprecipitated (IP) with an anti-CRT antibody and
probed with an anti-Pgp or an anti-CRT antibody by Western blotting (WB),
as reported in ‘Materials and methods’. The results shown here are repre-
sentative of two similar experiments, giving superimposable results.
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doxorubicin-sensitive and doxorubicin-resistant cells, suggesting
that the downstream effectors of nitric oxide worked at the same
extent in the two populations.
Similarly, if we increased the nitric oxide levels with a stimulus
different from doxorubicin, such as the iNOS inducer TNF-, the
synthesis of nitrites and the translocation of CRT occurred in HT29
and in HT29-dx cells with no appreciable differences, suggesting
that the lack of nitric oxide production in doxorubicin-treated
HT29-dx was not due to a defect in the iNOS induction pathway,
but rather to the inability to accumulate enough doxorubicin to
activate the NF-B signalling transduction.
Not all chemotherapeutic drugs exert pro-immunogenic
effects; some non-immunogenic drugs, such as etoposide, camp-
tothecine and mitomycin C, acquire pro-immunogenic properties
only when co-administrated with recombinant CRT [9]. We show
in the present work that the co-incubation with a nitric oxide donor
may produce the same effect: indeed cisplatin did not increase
nitric oxide levels and CRT exposure in HT29 and HT29-dx cells,
but all these events were induced when cisplatin was associated
to SNAP. Moreover when SNAP and doxorubicin were added
together, they had a small but detectable additive effect on CRT
translocation in HT29 cells, suggesting that 5 mol/l doxorubicin
did not exert a maximal translocation and that nitric oxide may fur-
ther increase the exposure of CRT elicited by doxorubicin in sen-
sitive cells. On the other hand, when doxorubicin was devoid of
effect, as it occurred in HT29-dx cells, the addition of SNAP
restored the translocation of CRT.
Every time we detected an increase of CRT translocation in
chemosensitive cells, we also observed an increased phagocytosis
by iDCs. On the contrary, although the CRT density was as high on
the HT29-dx cells surface as in HT29 cells (e.g. following TNF- or
SNAP), the phagocytosis of chemoresistant cells did not increase.
Our results suggest that nitric oxide was sufficient to promote the
CRT translocation followed by the phagocytosis in doxorubicin-
sensitive cells. The situation looks different in drug-resistant cells,
where nitric oxide was necessary to induce the exposure of CRT,
but this event was not sufficient to induce the uptake by iDCs.
Interestingly also untreated HT29-dx cells were less phagocytized
than HT29 cells: CRT was low in both the populations in this exper-
imental condition, so we wondered if other additional features
made doxorubicin-sensitive and doxorubicin-resistant cells differ-
ent as to their phagocytosis by iDCs. A striking difference between
HT29 and HT29-dx cells is the overexpression in the latter popula-
tion of Pgp, which is responsible of the drug-resistant phenotype.
We therefore evaluated whether this protein could play a role also
in the immunoresistance of HT29-dx cells.
Surprisingly we found that CRT was bound to Pgp, in a man-
ner dependent on the expression level of the latter. Indeed in HT29
cells Pgp was not co-immunoprecipitated with CRT, probably
because of the very low amounts of this ABC transporter. On the
other hand, in HT29-dx cells, where the efflux pump is abundant,
CRT clearly interacted with Pgp. Our results on the ER-enriched
fraction and on the plasma membrane fraction suggest that such
an association started in the ER membrane, where both CRT and
Pgp are present [24], and was not lost during the movement to the
cell surface. Nitric oxide did not alter the binding of CRT with Pgp,
since the interaction between them persisted in the presence of
SNAP. It is conceivable that the activity of the nitric oxide/cGMP
pathway is not specific for a single ER protein like CRT, but gener-
ically facilitates the traffic of microsomal vesicles from ER to
plasma membrane. Acting as a chaperon protein, CRT may bind
many other proteins synthesized in ER and help them in the
Fig. 7 Effect of Pgp knocking-down on CRT
exposure and HT29-dx cell phagocytosis.
Non-silenced HT29-dx cells (wt) or HT29-dx
cells silenced for Pgp (Pgp-) were incubated
for 6 hrs with fresh medium (CTRL), doxoru-
bicin (5 mol/l, DOX) or SNAP (100 mol/l,
SN), then subjected to the following investi-
gations. (A) Western blot detection of Pgp.
HT29-dx cells were grown for 72 hrs in the
absence (wt) or presence of siRNA
sequences (siR) targeting Pgp gene, as
reported in ‘Materials and methods’. When
indicated, a non-targeting scrambled siRNA
sequence (nt) was added instead of siRNA
for Pgp. The expression of Pgp was detected
by Western blot analysis, comparing HT29-
dx with untreated HT29 cells. The expression of the housekeeping protein GAPDH was measured as equal control loading. The the band density ratio
between Pgp and GAPDH was expressed as arbitrary units. Vs HT29: *P 
 0.05; versus HT29-dx wt: P 
 0.05. (B) The nitrite synthesis in the culture
supernatant (open bars) and the intracellular doxorubicin accumulation (hatched bars) were measured in duplicate, as described in ‘Materials and meth-
ods’. Data are presented as means 	 S.E. (n  4). For nitrite: versus CTRL wt: *P 
 0.05; versus CTRL Pgp-: P 
 0.05; versus DOX wt: P 
 0.01.
For doxorubicin: versus DOX wt: *P 
 0.05. (C) The surface expression of CRT, assessed by flow cytometry analysis as reported under ‘Materials and
methods’, was measured in duplicate. Data are presented as means 	 S.E. (n  4). Vs CTRL wt: *P 
 0.01; versus CTRL Pgp-: P 
 0.01; versus DOX
wt: P 
 0.002. (D) The phagocytosis rate of HT29-dx cells by iDCs was evaluated in duplicate by flow cytometry (see ‘Materials and methods’). Data
are presented as means 	 S.E. (n  3). Vs CTRL wt: *P 
 0.05; versus CTRL Pgp-: P 
 0.05; versus DOX or SN wt, respectively: P 
 0.02.
J. Cell. Mol. Med. Vol 15, No 7, 2011
1503© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
intracellular processing and folding: for example it has been
recently demonstrated that CRT forms complexes with collagen
type I in the ER of fibroblasts. This association plays a crucial role
in the trafficking of collagen from ER to Golgi apparatus and is
important to target the collagen fibres to their final destination in
the extracellular environment [25]. Because Pgp is actively syn-
thesized in drug-resistant cells, we may suppose that the ABC
transporter interacts with CRT during the quality control step in
the ER and that CRT acts as an escort protein for Pgp, accompa-
nying the latter to its definitive localization on the plasma mem-
brane. However, following this interaction, CRT looses at least one
of its functional properties, that is the peculiarity to function as a
docking protein for iDCs on tumour surface.
When the expression of Pgp was knocked down by specific
siRNAs, the CRT-operated phagocytosis was restored in HT29-dx
cells: in silenced cells doxorubicin was able again to accumulate, to
induce nitric oxide synthesis and CRT translocation and to promote
phagocytosis by iDCs. Also SNAP, which was capable to induce the
CRT exposure but not the phagocytosis in HT29-dx cells, became
an ‘eat me’ agent in Pgp-silenced HT29-dx cells, reproducing all the
effects exhibited in drug-sensitive HT29 cells. These data show that
Pgp, when overexpressed, inhibit the tumour cells phagocytosis
and play a role not only in the chemoresistance, but also in the
immunoresistance. At present we do not know the nature of the
binding between CRT and Pgp, and the mechanism of the Pgp-
mediated inhibition of phagocytosis. The ABC transporter might
exert a steric hindrance, due to its high molecular weight and abun-
dance on cells surface of resistant cells, impairing the correct
membrane presentation or clusterization of CRT and altering the
recognition of tumour cells by iDCs.
Chemo-immunotherapy is a very promising approach in 
the treatment of the most aggressive cancers, refractory to the
conventional anticancer drugs [16]; a better knowledge of the
mechanisms which regulate the chemo-immunoresistance to
doxorubicin in human cancer cells is certainly useful to optimize
the chemo-immunotherapeutic protocols. In our work we have
demonstrated that the association of nitric oxide releasing com-
pounds, which are widely used in the management of cardiovas-
cular diseases, to conventional anticancer drugs, may represent a
novel approach of chemo-immunotherapy in chemosensitive
tumours. As for the chemoresistant tumours, which we showed
are also immunoresistant, nitric oxide was able to restore the
sensitivity to the doxorubicin cytotoxic effects and the transloca-
tion of CRT [4, 6], but was not sufficient to trigger the activation
of iDCs against the tumour. However the refractoriness of 
drug-resistant cells to be phagocytized may be circumvented by
down-regulating the Pgp protein. Recently the selective silencing
of Pgp, followed by the administration of anticancer drugs, has
successfully arrested the growth of chemoresistant tumour in
mice xenografts, prolonging the overall survival of the animals
and showing new possibilities of combination therapies for
aggressive cancers [26]. Our work may suggest that the combi-
nation of nitric oxide releasing agents with therapeutic tools
down-regulating Pgp fully restores the functional role of CRT in
drug-resistant cells and might be successful in obtaining a rever-
sion of chemo-and immunoresistance in these cells.
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